SFDA to Withdraw One Parkinson's Drug From Market (China)
This article was originally published in PharmAsia News
Executive Summary
China's State Food and Drug Administration (SFDA) has announced it will phase out approval and distribution for Parkinson's disease drug Permax because it carries a serious risk of heart damage. In January this year The New England Journal of Medicine published two studies confirming a link between Permax and heart valve damage and disease. China will halt sale and use of this drug by Jan. 1, 2008, and today will phase out use by current Permax users because sudden cessation could jeopardize patients' health. Permax also is known as Pergolide Mesylate. The United States, Korea, and others already have halted sales. (Click here for more